50% off all subscriptions! ... left. Order NowOrder Now

Cara Therapeutics Stock Forecast NASDAQ:CARA

$12.80 (-4.05%)

Volume: 511k

Closed: Nov 26, 2021

Hollow Logo Score: -2.666

Cara Therapeutics Stock Forecast

$12.80 (-4.05%)

Volume: 511k

Closed: Nov 26, 2021

Score Hollow Logo -2.666
Which way will CARA go? Request
Key Stats
P/E Ratio 28.69
Beta 0.61
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 14 and the stock is extremely oversold on RSI14, but some stocks may continue to fall despite the high chance of a correction up. The low RSI lowers the general risk and the stock should be considered if other technical requirements like liquidity and risk-reward are meet.

Cara Therapeutics stock price down 4.05% on Friday
(Updated on Nov 26, 2021)

Sell candidate since 2021-11-17 Loss -13.75%

The Cara Therapeutics stock price fell by -4.05% on the last day (Friday, 26th Nov 2021) from $13.34 to $12.80. and has now fallen 10 days in a row. During the day the stock fluctuated 6.49% from a day low at $12.49 to a day high of $13.30. The price has fallen in 9 of the last 10 days and is down by -20.84% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -11 thousand shares and in total, 511 thousand shares were bought and sold for approximately $6.54 million.

The stock is at the lower part of a very wide and horizontal trend in the short term, and normally this may pose a good buying opportunity, though a breakdown through the bottom trend line at $12.69 will give a strong sell signal and a trend shift may be expected. Given the current horizontal trend, you can expect Cara Therapeutics stock with a 90% probability to be traded between $12.66 and $18.10 at the end of this 3-month period. A break of a horizontal trend is often followed by a large increase in the volume, and stocks seldom manage to go directly from the bottom of a trend up to the top. Stocks turning up in the middle of a horizontal trend are therefore considered to be potential runners.

Signals & Forecast

There are few to no technical positive signals at the moment. The Cara Therapeutics stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $13.81 and $14.96. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Tuesday, November 09, 2021, and so far it has fallen -29.44%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.

Support, Risk & Stop-loss

Cara Therapeutics finds support from accumulated volume at $12.72 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.81 between high and low, or 6.49%. For the last week, the stock has had a daily average volatility of 5.15%.

Cara Therapeutics is oversold on RSI14 (14). Some stocks may fall long and hard while being oversold on RSI, but stocks that are heavily oversold on RSI often pose good re-bounce chance and played well it can be a buy candidate.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Cara Therapeutics stock A Buy?

Cara Therapeutics holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -2.666

Predicted Opening Price for Cara Therapeutics of Monday, November 29, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price November 29, 2021 Current price
$12.86 $12.80 (Undervalued)
Sell Candidate Unchanged

Remember To Visit Our YouTube Channel

Analyst Ratings

On Aug 24, 2021 "Needham & Company LLC" gave "$26.00" rating for CARA. The price target was set to $15.11+5.8%.

Volatility and Risk
Daily Average Volatility: 5.15 %
Overall Risk: Very High High Medium Low Very Low
5.15 %
Daily Average Volatility
Overall Risk

Very High
Very Low

Support & Resistance

Resistance: $14.19
Price: $12.80
Support: $12.72

CARA Insider Trading Show all Trades



Last 100 transactions
Buy: 1 614 943 | Sell: 196 186 (Shares)
Date Action Amount Person Type
Nov 01, 2021 Sell 1 000 Goncalves Joana Common Stock
Oct 29, 2021 Buy 566 000 Posner Christopher Stock Option (Right to Buy)
Oct 29, 2021 Buy 142 000 Posner Christopher Common Stock
Oct 29, 2021 Buy 5 941 Posner Christopher Common Stock
Oct 27, 2021 Sell 1 000 Goncalves Joana Common Stock
Show all Insider Trades


Last 100 transactions
Buy: 1 614 943 | Sell: 196 186 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 13.67 6.82 %
13.36 4.41 %
13.17 2.91 %
Current price: 12.80
Support 12.55 -1.92 %
12.36 -3.42 %
12.05 -5.83 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 15.25 19.14 %
14.58 13.91 %
14.19 10.86 %
Current price 12.80
Support 12.72 -0.63%
12.70 -0.78%
0 .

Click to get the best stock tips daily for free!

About Cara Therapeutics

Cara Therapeutics Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system. Its lead product candidate includes I.V. CR845, which is in Phase III clinical trials for the treatment acute postop... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE